Antiallodynic interaction and motor performance of the pregabalin/thioctic acid and pregabalin/α‐tocopherol combinations in neonatal streptozotocin‐induced diabetic rats

Cruz-Álvarez, Lidia Elizabeth de la; Zúñiga-Romero, Ángel; Huerta-Cruz, Juan Carlos; Flores‐Murrieta, Francisco J.; Reyes-García, Juan Gerardo; Araiza-Saldaña, Claudia Ivonne; Rocha-González, Héctor Isaac

doi:10.1002/ddr.21473

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine the anorectic effect of mazindol, metformin or their combination, the reduction of the sweetened milk intake was measured, as previously described by Cruz-Álvarez et al (15). Rats were habituated for 7 days to drink sweetened milk for 90 min.…”

Section: Anorectic Effect Evaluationmentioning

confidence: 99%

Efficacy and safety of the metformin-mazindol anorectic combination in rat

et al. 2020

Self Cite

View full text Add to dashboard Cite

The current study investigates the anorectic interaction and safety of the mazindol-metformin combination in rats. Isobologram and interaction index were used to determine anorectic interaction between mazindol and metformin in the sweetened milk model. The safety profile of the mazindol-metformin combination was determined by measuring anxiety, blood pressure, hematic biometry and blood chemistry. An acute dose of mazindol and metformin administered per os, individually or as a mixture, has reduced the milk consumption in rats in a dose-dependent manner. Theoretical effective dose 40 (ED40t) did not differ from the experimental effective dose 40 (ED40e) obtained with the mazindol-metformin mixture in the anorexia experiments, by Student′s t-test. In addition, the interaction index confirmed the additive anorectic effect between both drugs. A single oral dose of ED40e mazindol-metformin mixture induced anxiolysis in the elevated plus-maze test. Moreover, oral administration of mazindol-metformin combination for 3 months significantly decreased glycemia, but not blood pressure nor other parameters of hematic biometry and blood chemistry. Results suggest that mazindol-metformin combination exerts an additive anorectic effect, as well as anxiolytic and hypoglycemic properties. Mazindol-metformin combination might be useful in obese patients with anxiety disorders or diabetes risk factors.

show abstract

Section: Anorectic Effect Evaluationmentioning

confidence: 99%

Efficacy and safety of the metformin-mazindol anorectic combination in rat

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The rationale for combining the anticonvulsant, pregabalin, with the antioxidant, alpha-lipoic acid (ALA), is supported by (1) good quality evidence of efficacy for pregabalin 12 and ALA 33 in neuropathic pain; (2) differing antinociceptive mechanisms, with evidence showing that ALA decreases nociceptive sensitivity via inhibition of T-type calcium (Cav3.2) channels, 25 whereas pregabalin inhibits N-type calcium channels, 28 which is further supported by evidence of additive analgesic effects in preclinical pain models 10 ; and (3) differing adverse effect profiles such that combining ALA with pregabalin is not expected to increase the frequency or severity of treatment-related adverse effects. Thus, we present the “PAin Improvement with Novel Combination Analgesic REgimens”—PAIN-CARE trial—a double-blind, randomized controlled trial to compare a combination of pregabalin with ALA to each monotherapy for the treatment of neuropathic pain.…”

Section: Introductionmentioning

confidence: 98%

Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial

Gilron,

Robb,

et al. 2023

PAIN

View full text Add to dashboard Cite

We compared a combination of the nonsedating antioxidant, alpha-lipoic acid (ALA), with the sedating anticonvulsant, pregabalin, vs each monotherapy to treat neuropathic pain due to peripheral neuropathies. In this randomized, double-blind, 3-period crossover trial, participants received oral ALA, pregabalin, and their combination—each for 6 weeks. The primary outcome was mean daily pain intensity at maximal tolerated doses (MTD); secondary outcomes included quality of life (SF-36), sleep (Medical Outcomes Study-Sleep Scale), adverse effects, drug doses, and other measures. Of 55 participants randomized (20—diabetic neuropathy, 19—small fiber neuropathy, and 16—other neuropathies), 46 completed 2 periods, and 44 completed 3. At MTD, the primary outcome of mean pain intensity (0-10) was 5.32 (standard error, SE = 0.18), 3.96 (0.25), 3.25 (0.25), and 3.16 (0.25) at baseline, ALA, pregabalin, and combination, respectively (P < 0.01 for ALA vs combination and pregabalin). Treatment differences were similar in subgroups with diabetic neuropathy and with other neuropathies. SF-36 total scores (higher number indicates better quality of life) were 66.6 (1.88), 70.1 (1.88), and 69.4 (1.87) with ALA, pregabalin, and combination (P < 0.05 for ALA vs combination and pregabalin). At MTD, there were no statistically significant treatment differences in adverse effects or drug doses. This trial demonstrates superiority of pregabalin vs ALA but provides no evidence to suggest added benefit of combining ALA with pregabalin to treat neuropathic pain.

show abstract

“…Rats in Sham+α-TOH group and CIRI+α-TOH group were injected with α-TOH (100 mg/kg) (Selleck) subcutaneously daily in the week before operation. 18 Rats in the Sham+NS group and CIRI+NS group were injected with the same amount of NS daily in the week before operation.…”

mentioning

confidence: 99%